Our Pipeline
Developing first-in-class small molecule drugs used in cancer treatments is Senhwa’s corporate mission and currently 2 main compounds CX-5461 and CX-4945 are ongoing phase I/II clinical trials in Australia, Canada, United States, Korea and Taiwan.
View More
Core Value
Senhwa has a strong Management Team with proven track records in developing new drugs and targeted agents. Headquartered in Taiwan, but with a vital operational base in San Diego, California, the Senhwa Team is well positioned to oversee the development of their compounds by collaborating with a diverse range of global investigators and service providers.
View More
Latest News +
-
Jul 02, 2020
Coronavirus Breakthrough: New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19
-
Jul 02, 2020
[Yahoo Finance]New Study Highlights Senhwa Biosciences Silmitasertib as Potential Treatment for COVID-19
-
Jul 01, 2020
[TAIPEI TIMES]Senhwa aims NT$1.5bn via 15 million shares
VISION
As a value-added development company, Senhwa aims to take innovative therapies that could impact the current standard of care and drive them through to clinical Proof-of-Concept.
CONTACT US
Please feel free to contact us if you have any questions
INVESTOR
For more information on our financial reports, please visit Investor Relations